In complex therapy, this enterosorbent is generally considered relevant for managing conditions where the body may experience a significant toxic burden. The primary therapeutic benefit supports a non-systemic reduction of this load, which contributes to easing related symptoms.

This medication is commonly used to provide supportive relief during acute toxic episodes such as food poisoning or infectious causes of acute diarrhea, and is also applied in addressing symptoms of chronic endotoxicosis and certain toxic-allergic manifestations. It helps address symptom clusters that may become intense or disruptive, including associated fever, malaise, headache, and skin discomfort.

The application is considered relevant in contexts involving heightened systemic burden, such as during episodes of sudden intoxication, or in scenarios where additional management of discomfort is required in conditions marked by increased physiological stress.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities and help patients cope more steadily with symptom fluctuations.”

The supportive benefit assists with maintaining a sense of stability and supports general well-being and day-to-day comfort when symptoms are more noticeable for patients managing chronic health challenges.

---

Quick Fact: Relief for Toxic Burden Symptoms The product is commonly used to help manage symptoms related to systemic imbalance and heightened physiological activity, assisting with maintaining functional stability during both acute and chronic symptomatic phases.

The official eligibility profile for Polifepan (Lignin Hydrolised) is defined by its role as a non-systemic enterosorbent, meaning it is not absorbed into the body and thus poses fewer restrictions related to systemic organ function.

Eligibility Scope

Category	Regulatory Status
Contraindicated Populations	Individuals with known Hypersensitivity to Lignin Hydrolised or conditions such as Atony of the Intestines (lack of bowel tone), Analgesic Gastritis, or Gastrointestinal bleeding (absolute prohibition).
Populations for whom use is not recommended	Patients with an exacerbation of gastric or duodenal ulcers. The granule formulation is restricted for use in patients with Diabetes Mellitus due to sugar content.
Age-Related Eligibility	Approved for use in Adults and generally established for use in Pediatric patients across various age groups.
Organ Function Status	Use is permitted in patients with Hepatic Insufficiency and Renal Insufficiency.
Pregnancy and Lactation	Use is formally contraindicated or not recommended during both pregnancy and breastfeeding (lactation), according to official labeling.

The regulatory criteria define eligibility by establishing absolute prohibitions tied to specific acute gastrointestinal conditions. Conversely, use is generally permitted for populations with impaired liver or kidney function, due to the drug's non-absorbed nature, but it is officially restricted during pregnancy and lactation.

The interaction profile for Poliſepan (Lignin Hydrolised) is exclusively defined by its function as a non-systemic enterosorbent. This mechanism dictates a pharmacokinetic interaction pattern based on physical adsorption within the gastrointestinal tract. Consequently, regulatory information outlines specific constraints regarding the co-administration of other drugs and the long-term use of the product.

Documented Interaction Constraints

Type of Constraint	Interacting Substances/Context	Official Requirement
Administration Timing	All other orally administered medicinal products.	A mandatory time interval of 1–2 hours must be maintained between the intake of Poliſepan and any other oral medicine to prevent reduced drug exposure.
Nutrient Exposure Risk	Vitamins (Group B, D, E, K) and Calcium.	Required co-administration of these supplements is stipulated during prolonged use to offset the documented risk of reduced intestinal absorption.

The core pharmacokinetic interaction officially documented is the reduction in systemic exposure of co-administered oral medicines and essential nutrients resulting from the non-specific physical binding capacity of the enterosorbent. This constraint establishes the mandatory timing separation rule to minimize drug-drug interaction and necessitates the supplemental intake of vitamins and calcium to manage the long-term risk of reduced nutrient absorption. Regulatory labeling does not contain statements regarding specific contraindicated drug combinations, or any metabolic (CYP enzyme), or transporter-mediated interactions.

The mechanism of action for Полифепан (Lignin Hydrolised) is defined by its function as a non-systemic enterosorbent, operating solely through physical and chemical surface interactions within the gastrointestinal lumen. The compound is not absorbed and does not interact with classical systemic molecular targets like receptors or enzymes.

Compound's Primary Mechanistic Targets and Type of Interaction

The Lignin Hydrolised polymer utilizes its large, porous surface area to physically bind (adsorb) and chemically attract (chemisorb) a wide array of entities, including exogenous microbial toxins, heavy metal salts, and harmful endogenous metabolites. This binding forms stable, non-absorbable complexes, initiating the mechanistic cascade by inhibiting the intestinal absorption of the bound substances.

---

Modulation of Elimination Kinetics and Systemic Concentration ️

By sequestering metabolites like excess bilirubin and waste products in the gut, the drug interrupts their normal enterohepatic recirculation, forcing their complete fecal elimination. This process influences the elimination kinetics of key circulating metabolites, leading to a decrease in the systemic concentration of circulating toxic agents, contributing to the compound's physiological effect profile.

Official Administration Guidelines

Polyphepanum (Polifepan) is an oral sorbent that must be prepared as a suspension immediately before use. Administration instructions define the dosage, timing, and preparation steps.

Feature	Guideline
Route of Administration	Oral
Preparation	Mix the required dose of powder or paste with 50 to 100 ml of water and stir until a uniform suspension is formed.
Timing	Administer the suspension 1 to 1.5 hours before scheduled meals or the intake of any other oral medications.

Dosing Schedule

Dosage is determined by age or body weight, and the drug is generally taken 3 to 4 times a day. Single-dose guidance includes:

• Adults and Children 7+ years: Typically 15 g (about 1 tablespoon) per dose. In some protocols, adults may be advised to take 0.5 to 1 g per kg of body weight.
• Children 4-6 years: Typically 5 to 7 g per dose.
• Children up to 3 years: Typically 3 to 5 g per dose.

Duration of Use

The total treatment duration is defined by the specific use case, such as 3-5 days for acute conditions or 10-15 days for chronic conditions. Repeat courses may be taken after a defined pause, for example, 10-12 days, if determined necessary by a healthcare professional.

Research Evidence / Overview of Studies for Полифепан

1. Evidence for Use in Acute Toxic Episodes and Diarrhea

Research exploring the use of Lignin Hydrolised for acute episodes, such as those associated with food poisoning or infectious causes of diarrhea, is documented in short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity in both children and adults. Researchers mainly examined outcomes describing episodic or acute changes, such as the duration of the diarrheal episode and the consistency of stools. Findings from these studies describe patterns observed in the symptoms of acute diarrheal illnesses. Evidence quality varies, and the generalizability of these patterns across diverse patient groups and settings is not fully established. The follow-up durations were limited, focusing only on the acute phase of illness.

2. Evidence for Use in Toxic-Allergic Manifestations

Lignin Hydrolised was evaluated in research exploring its role in conditions involving periods of heightened symptoms, such as the skin condition Atopic Dermatitis. Studies explored patient-reported outcomes describing perceived discomfort and clinical signs linked to the condition. In some research scenarios, Lignin Hydrolised was studied as part of a combination treatment, meaning the findings are linked to the combined intervention. Data for certain groups remain insufficient regarding the use of Lignin Hydrolised alone for these conditions. Because many studies involved combination therapies, comparative evidence is lacking to fully distinguish the specific contribution of the Lignin Hydrolised component.

3. What is Still Uncertain About Полифепан's Research

The evidence is derived from studies observing responses over defined time intervals, and evidence quality varies across studies. Several research limitation frames apply, including that the follow-up durations were limited in many key trials, and sample sizes were modest. Long-term outcomes are not well characterized in the available research, and there is limited information for long-term outcomes related to the durability of any observed changes.

Key Studies & References

1. A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis (NCT01113346)
2. [The use of the enterosorbent polifepan in the combined treatment of patients with dermatoses]
3. Filtrum 400 mg instructions for use (Indications and Properties of Hydrolyzed Lignin)

Common questions about Полифепан (FAQ)

Q: Can I take Полифепан at the same time as my regular vitamins?

A: Official instructions stipulate a mandatory one to two-hour interval between taking Полифепан and all other oral medications, including vitamins. This time separation is required to prevent the enterosorbent from reducing the absorption of other substances. Official guidelines also stipulate supplemental intake of vitamins and calcium for use during prolonged courses.

Q: What happens if I accidentally take more Полифепан than the recommended amount?

A: Polifepan is classified as a non-systemic adsorbent, meaning the active ingredient is not absorbed into the bloodstream or the body. Consistent with this non-systemic mechanism, official regulatory documents do not specify a unique toxicity profile related to accidental acute overdose.

Q: Is there a maximum number of days Полифепан is usually recommended for use?

A: Official administration guidelines define the standard duration of continuous use. For acute conditions, the treatment duration is typically 3–5 days, and for chronic conditions, it is usually 10–15 days. These time frames represent the maximum duration before an official pause or break in treatment is advised.

Q: What are the official restrictions for individuals with chronic bowel issues?

A: The drug is officially contraindicated for individuals diagnosed with specific gastrointestinal conditions. These include atonic constipation (lack of bowel muscle tone), analgesic gastritis, and gastrointestinal bleeding. Use is also not recommended during the exacerbation phase of gastric or duodenal ulcers.

Q: Is Poli/fepan regulated as a food supplement or as a drug?

A: Polifepan is officially regulated and registered as a medicinal product (drug). It is not regulated or classified as a food supplement.

Q: Can Полифепан be used by people who follow a vegan or vegetarian diet?

A: The active ingredient, Lignin Hydrolised, is a complex compound of natural origin derived from wood components. Official documents related to the active ingredient do not list animal-derived components.

Q: Can Полифепан be mixed with juice or other liquids before consumption?

A: Official regulatory instructions specify mixing the product exclusively with water to create the required uniform suspension before use. Following the preparation steps exactly as described in the official documents helps ensure the product is administered correctly.

Q: Why is Полифепан sometimes prescribed for allergies?

A: Official research has explored the drug's use in conditions involving acute or heightened symptoms, which are sometimes described as toxic-allergic manifestations, such as Atopic Dermatitis. This is consistent with its primary function as an enterosorbent to bind and eliminate various substances from the gut.

Q: Is there a risk of it causing vitamin deficiency if used repeatedly?

A: Official labeling states that prolonged or long-term use of the enterosorbent may potentially lead to the adsorption and loss of essential vitamins and minerals. This factor is why official guidelines include information on supplementing these nutrients during prolonged use.

Q: Is Полифепан a prescription drug or can it be bought over the counter?

A: According to official regulatory and pharmacy information, Poliſepan is described as a medicinal product available without a prescription. It is an over-the-counter drug.

Q: Is Полифепан the same type of product as activated charcoal?

A: No. Both products belong to the general class of enterosorbents, meaning they work by adsorption within the digestive tract. However, Полифепан’s active ingredient is Lignin Hydrolised, which is a different chemical structure than the carbon base used in activated charcoal.

Q: Does Полифепан absorb only harmful substances or beneficial ones too?

A: The active ingredient is a non-specific binder, meaning its action is not limited only to recognized toxins. Official documentation notes a risk of reduced absorption of essential substances, such as vitamins and calcium, especially during long-term use. This factor is why official guidelines include information on supplementing these nutrients during prolonged use.

Q: Are there any common side effects people report when using Полифепан?

A: The officially documented adverse effects are limited, with Constipation and Dyspepsia (indigestion) being listed as uncommon effects. Allergic reactions or hypersensitivity are classified as rare. These effects are primarily localized to the digestive system.

Q: Is it possible to become dependent on Полифепан if I use it for a long time?

A: Official regulatory documents do not contain statements regarding the potential for physical or psychological dependence related to the long-term use of this agent. This is consistent with its non-systemic mechanism, as the drug is not absorbed into the body.

Q: Does taking Полифепан affect the absorption of birth control pills?

A: Official instructions require a mandatory one to two-hour gap between Poliſepan and all other oral medicines, including contraceptives. This rule is in place to prevent the enterosorbent from physically binding and reducing the systemic exposure of the co-administered drug.

Q: Is Полифепан generally considered safe for children to use?

A: Official documentation confirms the drug is established for use in both adults and pediatric patients, with age-specific dosing protocols included in the administration guidelines.

Q: Does Полифепан have an expiry date, and how should it be checked?

A: The official shelf life is typically four years, provided the product is stored correctly under the mandated conditions. The specific expiry date is required to be printed on the product's primary and secondary packaging, as is standard for pharmaceutical products.

Q: Are there any restrictions on what I can eat or drink while using Полифепан?

A: The primary specific restriction mentioned in the official administration guidelines is the mandatory separation interval. The drug must be taken 1 to 1.5 hours before consuming any meals.

Q: Where does the active ingredient in Полифепан come from?

A: The sole active ingredient, Lignin Hydrolised, is a complex, high molecular weight polymeric compound. It is of natural origin, produced through a process called hydrolysis of wood components.

Q: Can I use Полифепан for mild stomach upset or indigestion?

A: Official documentation for the drug is structured around specific approved uses, such as for acute toxic episodes and associated diarrheal illnesses. Using it for mild, non-specific stomach upset is not explicitly defined in the official approved uses.

Q: Does Полифепан have any known effect on liver function?

A: Due to its non-systemic mechanism of action, the drug is not absorbed into the body and does not undergo metabolic processing by the liver. Consistent with this, official eligibility profiles state its use is permitted in patients with hepatic insufficiency.

Q: Does Полифепан contain any sugars or artificial sweeteners?

A: The official labeling notes that the granule formulation contains sugar, which leads to restrictions for use in patients with Diabetes Mellitus. Information on the presence of artificial sweeteners in the different formulations is not generally specified in the core regulatory documents.

Q: Is it true that Полифепан is used in veterinary medicine?

A: Bodies like the FDA regulate the lignin substance class for use as a component in animal feed. This indicates the substance’s use in animal agriculture, separate from its registration as a human medicinal product.

Q: Does the efficacy of Полифепан change if I take it with food?

A: Official instructions stipulate that the medicine must be taken 1 to 1.5 hours before meals. The purpose of this separation is to ensure the product's adsorption capacity is not compromised by co-ingestion of food.

Q: What should I do if the Полифепан powder is difficult to mix?

A: Official instructions advise mixing the powder or paste with 50 to 100 ml of water and stirring until a uniform suspension is formed. The quality of the mixing process can influence the final suspension.

Q: Does it matter what time of day I take Полифепан?

A: The official administration schedule is typically 3 to 4 times a day. The primary timing requirement is the mandatory 1 to 1.5 hour separation from meals and other oral medications, rather than a specific time of day.

Q: Is the product designed for immediate or prolonged release?

A: The product is classified as a non-systemic enterosorbent that is prepared as a suspension immediately before use. It acts through adsorption within the gastrointestinal tract, consistent with an immediate, non-delayed function, and is not described as a prolonged-release product.

Q: Are there any specific official warnings about using Полифепан with alcohol?

A: Official regulatory documents do not contain explicit warnings or contraindications related to the co-administration of alcohol. This absence of a systemic alcohol warning is consistent with the drug's non-systemic mechanism of action.

How to Store and Dispose of Polyphepan

To ensure the stability of Polyphepan (Lignin Hydrolised), specific storage conditions are mandated by regulatory labeling.

Official Storage Requirements

Requirement	Condition
Maximum Temperature	Must not exceed 25 C
Environment	Must be stored in a dry place
Packaging	Keep in the original container
Child Safety	Store out of the reach of children
Shelf Life	Typically 4 years, if stored correctly

Disposal Instructions

Disposal of any unused or expired Polyphepan must strictly follow local governmental regulatory requirements for pharmaceutical waste. The product should not be discarded via household trash or wastewater unless specifically authorized by local regulations.